Last edition
News about "EMA biosimilar tailored clinical approach"
Biocon's Pertuzumab Gets EMA CHMP Approval Nod
Biocon’s pertuzumab biosimilar has received a positive EMA CHMP opinion following review of its Marketing Authorisation (MA) application.
EMA Biosimilar Tailored Clinical Approach | 21/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members